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Penile cancer is an uncommon malignancy that has a devastating eﬀect on the patient while also being challenging to diagnose
and treat. By implementing preventive measures, we can decrease the incidence of this disease and improve the quality of life of
our patients. Early detection plays an important role in disease control and proper diagnostic modalities must be used in order to
accuratelyidentifythecanceranditsprogression.Primarypenilelesionsshouldbeinitiallyapproachedwhensurgicallyfeasibleand
clinically appropriate with penile preserving surgical techniques. Advances in inguinal lymph node detection and management,
has improved the clinical outcome of penile cancer. Advanced penile cancer still portends a poor prognosis and should be
approached via a multimodal treatment regimen. In this review, we address the importance of prevention, early detection, and
the contemporary management of primary penile lesions, as well as the advances in inguinal lymph node disease detection and
surgical treatment, for both localized and advanced disease.
1.Introduction
Penile cancer is an uncommon disease in the US and Europe
that has a devastating eﬀect on the patient while also being
challenging to diagnose and treat. A distinction between
benign and malignant penile neoplasms must be made in
order to oﬀer the most eﬀective treatment [1]. In 2010, the
new cases of penile cancer in the United States are about
1,250 with 310 deaths, with an incidence rate of 0.3 to 1.8
per 100,000 [2, 3] .P e n i l ec a n c e ri sm u c hm o r ec o m m o ni n
African, Asian, and South American countries, constituting
about 10% of malignant disease in these countries and
thus posing a considerable health concern [1, 4]. Notably,
Paraguay and Uganda have an incidence rate of 4.2 and 4.4
per 100,000, respectively [4]. The lowest incidence is found
in Israeli Jews (0.1/100,000) [3]. Cancer of the penis most
commonly aﬀects men between the ages of 50–70, with only
19% at ages <40 and 7% <30 [3]. Squamous cell carcinoma
of the penis was found to be 43% greater in men from
countries where the poverty level is >20% [3].
2. Risk Factors
The presence of an intact foreskin has been identiﬁed as an
important risk factor for developing penile cancer. Maden
et al. [5] found that the risk of penile cancer was 3.2-times
greater among men who had never been circumcised relative
to men circumcised at birth and 3.0-times greater among
mencircumcisedaftertheneonatalperiod[3,5].Inaddition,
penile cancer is rarely seen in Jews, as they are circumcised at
birth [3].
A history of phimosis is also a signiﬁcant risk factor. 25–
60%ofpatientswhohadahistoryofphimosisdeveloppenile
cancer[3].Hellbergetal.[6]performedaretrospectivestudy
of 244 men with penile cancer and 232 matched controls.
The relative risk of penile cancer among men with phimosis
was 64.6 [3, 6]. Phimosis leads invariably to retention of the
normally desquamated epidermal cells and urinary products
(smegma) resulting in conditions of chronic irritation with
or without bacterial inﬂammation of the prepuce and the
glans [4]. The frequency of phimosis in men with penile2 Advances in Urology
carcinomaishigh,rangingfrom44%to85%[4,7].However,
there is no supporting evidence of the role of smegma as a
carcinogenandis,therefore,notbelievedtocontributetothe
development of penile cancer.
Several studies have also identiﬁed smoking as an asso-
ciated risk factor for the development of penile cancer [3].
Balanitisandpenileinjuryhasalsobeenfoundtoincreasethe
risk of penile cancer [3, 5, 6]. Number of sexual partners and
history of genital warts or other sexually transmitted disease
may also play a part in the risk for developing cancer of the
penis [4, 8]. HPV types 16 and 18 have a strong correlation
with penile carcinoma, reported as 25–94.7% of cases with
type 16 and 10.5–55.4% with type 18 [3, 5, 9]. Review of the
literature revealed that about 45–80% of penile cancers are
related to HPV [4, 7, 8, 10, 11].
2.1. Goal. The goal of this review is to highlight the current
practicesinprevention,detection,andtreatmentforprimary
penile lesions as well as advanced penile cancer with an
emphasis on recent data and future prospects for the
management and diagnosis of penile carcinoma.
3. Prevention
3.1. Circumcision. As stated previously, there is much evi-
dence pointing to the association of an intact foreskin
with the development of penile cancer. Circumcision in
early childhood could prevent phimosis and other risk
factors, such as HPV infection, thereby reducing the risk of
developingpenilecancer[4,12].Multiplestudieshaveshown
that the vast majority of men with penile carcinoma are
uncircumcised [12]. In well-developed countries where the
incidenceofpenilecancerislow,thispreventivemeasuremay
not be necessary. However, other less developed countries
with poor hygiene may attain a greater and much more
tangible beneﬁt with circumcision [12]. In addition, cir-
cumcised men with female partners known to have cervical
intraepithelial neoplasia (CIN) had a lower rate of develop-
ing PIN compared to men who were uncircumcised [13, 14].
Unfortunately, the advantage of adult circumcision in the
prevention of penile cancer has not been well established.
3.2. HPV. Since HPV plays a major role in the development
of penile carcinoma, it is a prime target for prevention.
Thus far, there are two diﬀerent types of HPV vaccines:
GARDASIL, a quadrivalent vaccine that targets types 6, 11,
16, and 18; and Cervarix, a bivalent vaccine which targets
HPV types 16 and 18 [12]. It has been shown that the sero-
conversionaftervaccineisat99.1–100% withupto5yearsof
protection after vaccination in boys 9–15 years old [15, 16].
Unfortunately, long-term data are not yet available and thus
can only be assumed that male vaccination of HPV can
prevent associated penile cancer development [12]. Addi-
tionally,condomusehasbeenshowntoeﬀectivelyreducethe
risk of developing genital warts among partners [17].
Although there is evidence that suggests that there is a
link between smoking and penile cancer [5], the impact of
smoking cessation would not likely alter the incidence and
management of penile cancer. There is no clear evidence
between the connection of poor hygiene and the develop-
ment of penile cancer. However, the greater incidence of
penile carcinoma in third-world countries and the currently
available data suggest that poor genital hygiene may play
a role in the development of penile cancer [3, 4, 12, 18].
Psoralen Plus Ultraviolet Light A (PUVA) treatment for pso-
riasis has been shown to increase the incidence of squamous
cell carcinoma of the penis by 286-times that of the general
population[19,20].Therefore,patientsundergoingthiskind
of therapy should be advised to use genitalia shielding as well
as close observation for any penile lesions [12].
4.EarlyDetectionandDiagnosis
Penile carcinoma usually presents with a visible or palpable
lesion on the penis [21]. It can also be associated with pain,
discharge, bleeding, or foul odor [21]. It has been shown that
the glans penis is the most common site for primary disease
[22]. There is a signiﬁcant delay between initial symptoms
and seeking medical attention. Narayana et al. [23] showed
that only 48% of men sought treatment after 6 months with
symptoms, 21% waited beyond 6 months to up to a year, and
30% waited for over a year before seeking medical attention.
4.1. Staging. Based on changes proposed in 2009 by the
AJCC, the 2010 TNM staging system was revised as shown
in Table 1 [21].
A high index of suspicion for penile cancer must be
maintained in men with lesions on the penis, especially if
there are known risk factors present. A careful history and
examinationarekeytohelpcharacterizethelesionanddeter-
mine further diagnostic steps. The physical exam can be sup-
plemented by ultrasonography in order to more accurately
estimate lesion size and anatomic relations to the tunica
albuginea, corpus cavernosum, and urethra [21, 24–26].
Moreover, the 2004 European Association of Urology (EAU)
identiﬁed penile ultrasound as the initial diagnostic test of
choice in determining depth of tumor penetration [27, 28].
CT imaging is not considered an imaging modality of
choiceforpenilecancerduetoitspoorvisualizationofpenile
tissue planes and thus ineﬀective in evaluating the tumor
stage of the cancer [27]. In a small study, the combination
of PET/CT imaging was shown to have a sensitivity and
speciﬁcity of 75% for detecting primary penile tumors [29],
but remained to be ineﬀective in determining tumor stage
[27]. Cavernosography has been shown to successfully stage
patients [30]; however, it is limited in its ability to evaluate
tumor beyond the corporal bodies [27].
MRI has been shown to provide adequate staging
capabilities when combined with pharmacologically induced
penileerection[31].Itisthemostsensitiveimagingmodality
for penile carcinomas due to its superior soft tissue contrast
and assessment of penile fascial planes [27]. In addition,
endoluminal coils may also be used to enhance the MRI
images [32].
The AJCC states that a pathologic diagnosis must be
made, requiring the use of either punch, excisional, or
incisional biopsy [21, 33].Advances in Urology 3
Table 1: TNM staging system for penile cancer.
Deﬁnitions of TNM
Primary tumor (T)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ
Ta Noninvasive verrucous carcinoma
T1a Tumor invades subepithelial connective tissue without LVI
and is not poorly diﬀerentiated (i.e., G3-4)
T1b Tumor invades subepithelial connective tissue with LVI or is
poorly diﬀerentiated
T2 Tumor invades corpus spongiosum or cavernosum
T3 Tumor invades urethra
T4 Tumor invades other adjacent structures
Regional lymph nodes (N)
Clinical stage deﬁnition Pathologic stage deﬁnition
NX Regional lymph nodes cannot be assessed Regional lymph nodes cannot be assessed
N0 No palpable or visibly enlarged inguinal lymph nodes No regional lymph node metastasis
N1 Palpable mobile unilateral inguinal lymph node Metastasis in a single inguinal lymph node
N2 Palpable mobile multiple or bilateral inguinal lymph nodes Metastasis in multiple or bilateral inguinal
lymph nodes
N3 Palpable ﬁxed inguinal nodal mass or pelvic
lymphadenopathy unilateral or bilateral
Extranodal extension of lymph node
metastasis or pelvic lymph node or lymph
nodes unilateral or bilateral
Distant Metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
Reprinted with permission from Barocas and Chang [21].
5. PrimaryPenileLesions
The surgical management of a malignant penile lesion
depends on the grade and stage of the disease [34]. The
gold standard treatment for primary penile lesions remains
to be total or partial penectomy. This standard therapy of
total/partial penectomy for penile cancer achieves local con-
trol rates above 90% but also causes signiﬁcant disﬁguration,
leading to loss of function and psychosexual morbidity [35].
However, new evidence has shown that a 5–10mm
margin is as safe as a 2cm surgical margin [36] and has been
recommended by the EAU [35, 37]. It has been shown that
these smaller margins of 10–20mm provide adequate tumor
control [36, 38, 39].
5.1. CIS. First line therapy for carcinoma in situ (Tis) is
with topical chemotherapy using 5% 5-ﬂuorouracil (5-FU)
cream for 6 weeks. Studies have shown good sustained
r esponseratesat5yrs[40];however,morestudiesareneeded
to conﬁrm this data as well as the use of Imiquimod as
second-line therapy [34, 41]. CO2 and Nd-YAG lasers have
also proved to be eﬀective in the treatment of Tis [42],
with no signiﬁcant diﬀerences in recurrence and survival
among patients with partial penectomy, radiotherapy, or
laser therapy [43]. However, its use in T2 disease has
been shown to increase the risk of nodal spread [44], thus
stressingtheimportanceofproperstaging,management,and
followup for the diﬀerent types of penile cancer.
Intractable CIS may be managed surgically by a total
glans resurfacing technique used for Balanitis xerotica oblit-
erans [45] that has proven to be eﬀective for CIS [34, 46].
Circumcision is also eﬀective for prepuce lesions; however,
glans removal and reconstruction oﬀer better protection
[35]. Complete glansectomy may be required if urethra is
involved [35]. Studies have shown that recurrence rates
for these conservative surgeries are between 3.1–31.4%
[35]. Tumors less than 1cm in size are ideal for Mohs
micrographic surgery [35], and can provide maximal chance
of normal tissue preservation and function [47].
5.2.T1. Widelocalexcisionwithprimaryclosureoftheglans
is appropriate if there is no urethral involvement [34]. Larger
lesion may require split skin or full thickness graft to cover
the defect. Recurrence rates are reported to be at 50% after 2
years [48], thus requiring careful patient selection and close
surveillance [34]. Bandieramonte et al. [49] studied a total
of 224 patients with T1 disease who underwent CO2 laser
excision for penile carcinoma treatment. Complete excision
was achieved in 98.7% at lateral margins and 96.9% in the
deep margins. The study had a 10-year recurrence rate of
17.5% and a 10-year amputation rate of 5.5%, concluding4 Advances in Urology
that early stage penile carcinoma can be treated with organ-
sparing laser therapy [49].
5.3. T2. The new TNM staging system does not diﬀerentiate
between T2a with invasion into the corpus spongiosum,
and T2b with tunica or corpora cavernosa invasion. Studies
suggest that a higher rate of lymph node metastasis is seen
in T2b cavernosum invasion [35]. If disease is limited to
the glans, total glansectomy with excision of the glans penis
from the corpora cavernosa is appropriate [34]. Involvement
of the tunica albuginea and/or corpora cavernosa by the
cancer rules out conservative surgery [35]. In most cases,
partial penectomy is the appropriate therapy and total
penectomy with phalloplasty is warranted if the tumor
extends proximally [34].
5.4. Radiotherapy. Usually indicated for T1-T2 tumors of
less than 4cm and delivered via external beam radiotherapy
or brachytherapy [35]. Studies have shown external beam
radiotherapy to have a 5-year overall survival rate of 88%,
but at the same time carries a higher relapse rate than
penectomy[50].Brachytherapyhasanoverallsurvivalof69–
78% with preservation of the penis in 86% of cases [35, 51].
However, external beam radiotherapy and brachytherapy are
associated with severe complications down the line, such as
urethral stenosis, telangiectasia, ﬁbrosis/atrophy, and penile
necrosis resulting in amputation [35, 51, 52]. EAU guidelines
for radiotherapy (including brachytherapy) limits its use for
only T1-T2 tumors of the glans or sulcus and only palliative
external beam radiation for locally advanced metastatic
disease [35, 37]. Chronic ulcers or nonhealing areas after
radiotherapy should be considered tumor recurrence until
proven otherwise [34, 53].
5.5. Chemotherapy. T h e r ea r en ol a r g er a n d o m i z e dt r i a l s
concerning chemotherapy comparing one regimen versus
another. Neoadjuvant chemotherapy has shown promising
results with high response rates and pathological remissions
with combination regimens such as bleomycin, methotrex-
ate, and cisplatin [35]. Agents targeting angiogenesis or
COX-2 pathways may hold promise in treating penile cancer
[35]. Speciﬁcally, cetuximab has emerged as an eﬀective
therapy option for head and neck squamous cell carcinoma.
Recent data has shown cetuximab to provide signiﬁcant
improvement in regional control and overall survival [54].
There are several ongoing trials with cetuximab and its
eﬃcacy on head and neck SCC that have thus far shown
promising results [55].
6. InguinalLymph Nodes
Inguinal lymph node dissection (ILND) is standard practice
for patients with lymph node metastasis or patients with
high-risk primary penile tumors (T2 or greater, >50%
diﬀerentiated tumor) [56]. Unfortunately, complications
are common and can have signiﬁcant morbidity, such as
lymphedema, skin necrosis, and hematoma [56]. Therefore,
it is important to accurately determine the patients that are
in need of ILND via imaging, biopsy, and minimally invasive
techniques if metastasis is detected [57].
The presence and degree of lymph node involvement in
penile cancer plays a major role in prognosis [27]. Initial
assessment is by physical exam. About 50% of patients with
penile cancerhave palpable lymphadenopathy, with onlyhalf
of these actually turning out to be nodal metastases [27].
The use of antibiotics for a 2–6 week period has become
common practice in order to distinguish between metastatic
disease or inﬂammatory nodal response [27]. It has been
shownthatpalpablelymphnodesthatremainafterantibiotic
treatment have 90% chance of metastatic spread [27, 58].
There is evidence to suggest that it may be more beneﬁcial
to undergo FNA cytology to evaluate palpable inguinal
lymphadenopathy for metastatic penile cancer without the
need for prolonged antibiotic treatment [59].
NomogramdevelopedbyFicarraetal.[60]forpredicting
probability of lymph node involvement shown in Figure 1.
High-resolution ultrasound and color Doppler may be
used to assess palpable lymph nodes via detecting abnormal-
itiesinarchitectureandvascularity[61].WithcolorDoppler,
it has been noted that metastatic nodes show peripheral
vascularity while reactive nodes show a hilar perfusion
pattern [27, 61]. But the sensitivity and speciﬁcity of this
study may be inadequate unless combined with ﬁne-needle
aspiration cytology [27, 62]. Combination of FNA with US
has shown to have 40% sensitivity and 100% speciﬁcity
[63], and has been suggested as the initial investigation for
clinically palpable nodes in patients with high risk of lymph
nodes metastases [64].
Cross-sectional imaging such as CT and MRI rely on
changes in size and thus have been proven to be ineﬀective
intheevaluationoflymphnodemetastases[27,64].PET/CT
has been shown to have a high diagnostic accuracy with 90%
sensitivity and 100% speciﬁcity in the setting of cytologically
proven inguinal node metastases [65], but is inadequate in
patients with nonpalpable nodes [66].
Lymphotropic nanoparticle-enhanced MRI (LNMRI) is
a new and promising noninvasive imaging study for lymph
node staging. LNMRI was shown to have a sensitivity of
100% and a speciﬁcity of 97% in a recent small study [67].
In the same study, it was shown that LNMRI can accurately
detect lymph node metastasis even in patients without pal-
pable inguinal nodes [27, 67]. Thus, this imaging modality
may be eﬀective in determining whether a patient should
undergounilateralversusbilateralILND[27].Unfortunately,
this study is not widely available and requires lengthy
interpretation by the radiologist. Moreover the contrast used
has not been FDA approved and is not available in Europe
anymore [27].
Diﬀusion-weighted MRI is another imaging modality
that provides structural information about diﬀerent tissues.
When combined with LNMRI, it provides an eﬀective
and faster tool for the evaluation of inguinal lymph node
metastases [24, 68].
Dynamic sentinel lymph node biopsy (DSNB) has been
established as the modality of choice for nodal evaluation
in patients with melanoma [27]. Initial studies of DSNB
in the evaluation for penile cancer nodal spread revealedAdvances in Urology 5
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Figure 1: Nomogram predicting the probability of lymph node metastasis for penile cancer. Reprinted with permission from: Ficarra et al.
[60].
high false-negative rates between 22–77% [27]. However,
after certain technical modiﬁcations this high false-negative
rate dropped [27]. A recent study of DSNB combined with
ultrasound-guided FNA revealed a negative predictive value
of100%[27,62].Also,Leijteetal.[69]foundDSNBtohavea
sentinel node identiﬁcation rate of 97% with a false negative
rate of 7%.
6.1. Inguinal Lymph Node Dissection. Inguinal lymph node
dissection (ILND) can have signiﬁcant morbidity [56].
Therefore, it is important to accurately determine the
patients that are in need of ILND via imaging, biopsy, and
minimally invasive techniques if metastasis are detected [57].
Modiﬁed (limited) ILND consists of a shortened skin
incision with preservation of saphenous vein and subcu-
taneous tissues superﬁcial to Scarpa’s fascia; no dissection
lateral to femoral artery or caudal to the fossa ovalis, without
Sartorius muscle transposition [64, 70]. However, it has
been shown that modiﬁed ILND has up to a 5.5% risk of
leaving occult metastasis [64, 71]. Radical (complete) ILND
is described by Daseler et al. [72]a n dc a nb ec u r a t i v ei f
metastasis is limited to the inguinal nodes [64].
Video endoscopic inguinal lymphadenectomy (VEIL)
is a new minimally invasive procedure that can result in
lower complication rates and shorter hospitalization stay
[64] without compromising oncologic results [35, 73]. A
recent study revealed that VEIL had a morbidity rate of only
15% while standard open ILND had a 70% morbidity rate
[73].Inaddition,thenumberofnodesremovedwasthesame
for VEIL as it is for open ILND, while also showing no local
or systemic relapse after a median followup of 33 months
[35, 73]. However, data is still lacking in this promising new
treatment modality for ILND and would beneﬁt from larger
multicenter trials with an extensive follow-up period.
The question remains whether or not bilateral ILND is
warranted when unilateral disease is discovered. Studies have
shown that presence of positive nodes on one side has an
incidence of positive nodes on the contralateral side of about
20–60% [64, 74]. More recently, it has been suggested that
with greater than 2 inguinal lymph node metastasis, there is
30% of occult contralateral involvement [64, 75].
On the other hand, a recent study revealed that the
size of the sentinel lymph node during DSNB was the only
signiﬁcant prognostic variable for additional lymph node
involvement, with a node of less than 2mm to suggest no
additional nodal involvement, and thus sparing contralateral
ILND [64, 76]. Pelvic lymph node involvement and the need
for PLND is controversial with variable data on the matter
[64]. Studies range from recommending PLND based on
grade of primary tumor, to number of positive nodes in
ILND [64]. The involvement of Cloquet’s node has also
been studied to predict the likelihood of pelvic lymph
node spread and the need for PLND [64] .Ar e c e n ts t u d y
showed that lymph node metastasis in Cloquet’s node has a
sensitivity of 30% and speciﬁcity of 94% for pelvic lymph
node involvement [64, 77].6 Advances in Urology
7.AdvancedPenileCancer
Advanced primary penile cancer with bulky adenopathy
(>3cm) warrants penectomy with groin dissection [78]. If
nodes are unresectable, a multimodal approach would pro-
videthebestcancercontrol[78].Neoadjuvantchemotherapy
may be eﬀective in downsizing the initially inoperable
metastasis to allow for surgical removal [52]. Agents such
as bleomycin, methotrexate, 5-FU, ifosfamide, and cisplatin
each alone have a response rate of only 20% [52, 79, 80].
Nevertheless, combination regimens of these chemother-
apy agents have yielded greater response rates of 25–72%
[52, 81].
The combination of bleomycin, methotrexate, and cis-
platin have been studied in a prospective clinical trial that
revealed an overall response rate of 32.5% with a median
response duration of 16 weeks and median survival time
of 28 weeks [78, 82]. The high toxicity levels and degree
of eﬃcacy for this combination suggest that this may be
a poor choice for adjuvant or neoadjuvant chemotherapy
[78, 82]. Recent studies have shown promising data that
a combination neoadjuvant chemotherapy of paclitaxol,
ifosfamide, and cisplatin prior to surgery is well tolerated
and had signiﬁcant response in patients with bulky lymph
node metastasis with 36.7% of patients remaining free of
recurrence [83–85]. It has also been reported that adjuvant
chemotherapy with a combination of cisplatin, 5-FU, and
docetaxol would be beneﬁcial in advanced disease [52].
Recent EUA practice guidelines advocate for neoadjuvant
chemotherapy for locally advanced disease using a combina-
tion regimen with follow-up surgical resection [37, 86].
Radiotherapy may also play an important role in the
initial treatment of unresectable lymph node metastasis [78].
Muchinformationregardingsquamouscellcarcinomaofthe
penis is better understood with larger studies regarding SCC
of the vulva and anal canal [78]. Several large randomized
studieshaveshownthatthecombinationofchemoradiother-
apy with surgical treatment is an eﬀective and well-tolerated
management for anal and vulvar cancer [78]. Thus far, there
have been no large randomized trials for penile cancer. Thus,
extrapolation of this data into the realm of penile carcinoma
management would suggest that inoperable advanced penile
cancer may best be treated initially with chemoradiotherapy
followed by nodal dissection [78].
The relationship between epidermal growth factor recep-
tor (EGFR) and squamous cell carcinoma in other areas,
such as the head and neck, have been well studied resulting
in targeted agents against the receptor with improved
survival and response to radiotherapy [54, 86]. A recent
retrospective study by Carthon and colleagues [87] revealed
the use of erlotinib alone, cetuximab, or cetuximab plus
cisplatin had an overall survival range of 2.8 months to
48 months with median time to disease progression in
the range of 0.37 to >37 months [86]. The potential
merit of neoadjuvant chemotherapy plus/minus targeted
therapy with EGFR inhibitors followed by consolidative
surgical resection is of signiﬁcant clinical interest, and we
await results of planned phase II prospective trials in this
regard.
8. Conclusions
Penile carcinoma is rare in the United States and Europe,
but is an important cause of morbidity and mortality in
many other countries [1–4]. Therefore, it is important to
implement preventative measures to decrease the incidence
of disease and improve quality of life [4, 12].
Early detection plays a vital role in disease control and
the proper diagnostic modalities must be used in order to
accurately identify the cancer and its progression. The use of
imaging in combination with biopsy is an eﬀective means in
determining disease stage and grade [21, 27, 33].
Primary penile lesions should be initially approached
with penile-preserving modalities including Mohs, CO2
and Nd-YAG lasers, and chemo/brachytherapy [34, 35].
ILND should be undertaken after proper assessment for
metastatic spread to the nodes via DSNB in combination
with FNA cytology [27, 62, 69]. The use of LNMRI has
shown promise as a new tool for detecting lymph node
metastasis and presents as possible standard future approach
to the evaluation of inguinal lymph nodes [27, 67]. The
degree of ILND depends greatly on the extent of lymph
node involvement and grade [27]. VEIL has proven to be
an eﬀective treatment option for ILND with a superior
complication rate versus open nodal dissection [35, 64, 73].
Further data regarding its use and the diﬀerent approaches
to metastatic lymph node disease management is essential
and would greatly beneﬁt the advancement of penile cancer
care.
Advanced penile cancer holds a poor prognosis and must
be approached via a multimodal treatment regimen that
includes neoadjuvant chemotherapy followed by surgical
resection [78]. In select cases, the use of radiotherapy
has been shown to be eﬀective in the reduction of bulky
nonresectable disease to allow for surgical removal [78].
The chemotherapy combination that has so far shown to
be the most eﬀective and well tolerated is the paclitaxol,
ifosfamide, and cisplatin combination [37, 78, 83–86].
However, large randomized trials are lacking in this area and
would shed light as to the best therapy for advanced penile
cancer.
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